(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.62%) $83.24
(0.17%) $1.760
(0.36%) $2 406.70
(1.29%) $28.75
(-1.17%) $943.30
(-0.14%) $0.938
(-0.28%) $11.01
(0.55%) $0.808
(-0.96%) $93.00
Live Chart Being Loaded With Signals
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies...
Stats | |
---|---|
Today's Volume | 342 640 |
Average Volume | 359 733 |
Market Cap | 201.37M |
EPS | $0 ( 2024-04-01 ) |
Next earnings date | ( $-0.420 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.74 |
ATR14 | $0.0190 (0.28%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-28 | Nicholson, C. David | Buy | 70 311 | Stock Option (Right to Buy) |
2023-12-28 | Steinhart Richard I | Buy | 70 311 | Stock Option (Right to Buy) |
2023-12-28 | O'loughlin Steve | Buy | 253 123 | Stock Option (Right to Buy) |
2023-12-28 | Shetty Ajit | Buy | 70 311 | Stock Option (Right to Buy) |
2023-12-28 | Seth Sandesh | Buy | 984 367 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 13 159 883 | Sell: 1 707 212 |
Volume Correlation
Actinium Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Actinium Pharmaceuticals Correlation - Currency/Commodity
Actinium Pharmaceuticals Financials
Annual | 2023 |
Revenue: | $81 000.00 |
Gross Profit: | $-709 000 (-875.31 %) |
EPS: | $-1.830 |
Q4 | 2023 |
Revenue: | $81 000.00 |
Gross Profit: | $-118 000 (-145.68 %) |
EPS: | $-0.340 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-200 000 (0.00 %) |
EPS: | $-0.490 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-209 000 (0.00 %) |
EPS: | $-0.580 |
Financial Reports:
No articles found.
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators